StockData
Merck & Co., Inc. logo

Merck & Co., Inc.

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$149.52+3.19 (+2.18%)

Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%

Merck Keytruda (pembrolizumab by Quarter

Keytruda (pembrolizumab — PD-1 immuno-oncology franchise) — U.S. sales ($M) ($M)

QuarterlyAnnual

Merck Keytruda (pembrolizumab: $4,611M in Q2 2026, down 2.9% from a year earlier.

Latest, Q2 2026
4,611
Period ended Jun 30, 2026
Change on a year earlier
-2.9%
4,749 in Q2 2025
History
39 quarters
Since Q4 2016
Sources
31
Documents cited below

Where the Q2 2026 figure comes from

“|| Keytruda | 7,904 | 7,956 | -1 | 4,611 | 4,749 | -3 | 3,293 | 3,207 | 3”

Source: Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗

Reported in Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedKeytruda (pembrolizumab — PD-1 immuno-oncology franchise) — U.S. sales ($M) ($M)Year on yearSource
Q2 2026Jun 30, 20264,611-2.9%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q1 2026Mar 31, 20264,599+6.8%Form 10-Q (filed 2026-05-04) ↗
Q4 2025Dec 31, 20254,892+1.1%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q3 2025Sep 30, 20254,879+8.4%Form 8-K (tm2529620d1_ex99-1.htm, filed 2025-10-30) ↗
Q2 2025Jun 30, 20254,749+7.6%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q1 2025Mar 31, 20254,308+4.6%Form 8-K (tm2512885d1_ex99-1.htm, filed 2025-04-24) ↗
Q4 2024Dec 31, 20244,841+21.9%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q3 2024Sep 30, 20244,500+18.6%Form 8-K (tm2529620d1_ex99-1.htm, filed 2025-10-30) ↗
Q2 2024Jun 30, 20244,412+14.2%Form 8-K (tm2521736d1_ex99-1.htm, filed 2025-07-29) ↗
Q1 2024Mar 31, 20244,119+18.2%Form 8-K (tm2512885d1_ex99-1.htm, filed 2025-04-24) ↗
Q4 2023Dec 31, 20233,972+17.6%Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Q3 2023Sep 30, 20233,795+13.9%Form 8-K (tm2426878d1_ex99-1.htm, filed 2024-10-31) ↗
Q2 2023Jun 30, 20233,863+20.8%Form 8-K (tm2420272d1_ex99-1.htm, filed 2024-07-30) ↗
Q1 2023Mar 31, 20233,485+25.4%Form 8-K (tm2412490d1_ex99-1.htm, filed 2024-04-25) ↗
Q4 2022Dec 31, 20223,378+27.1%Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗
Q3 2022Sep 30, 20223,331+29.1%Form 8-K (tm2328962d1_ex99-1.htm, filed 2023-10-26) ↗

Breakdown

What makes up keytruda (pembrolizumab

Cite this data

StockData. (2026). Merck Keytruda (pembrolizumab ($M), quarterly Q4 2016–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-keytruda-us

See every metric in the Merck KPI table. Data updated Oct 26, 2026.